TET2 and T-cell non-Hodgkin lymphoma: Similarly, hypomethylating agents have been explored in T-cell lymphomas with a TFH phenotype given the known efficacy of this mechanism in myeloid disorders enriched for mutations in TET2 and DNMT3A, mutations that are similarly frequent in T-cell lymphomas with a TFH phenotype [54,55,56,57].